PL1817006T3 - Liposomalny preparat do doustnego podawania glutationu (zredukowanego) - Google Patents

Liposomalny preparat do doustnego podawania glutationu (zredukowanego)

Info

Publication number: PL1817006T3
Authority: PL; Poland
Prior art keywords: glutathione; reduced; oral administration; liposomal formulation; liposomal
Prior art date: 2004-11-07

Application number

PL05851408T

Other languages

English (en)

Inventor

F Timothy Guilford

Original Assignee

F Timothy Guilford

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-07

Filing date

2005-11-07

Publication date

2013-03-29

2005-11-07 Application filed by F Timothy Guilford filed Critical F Timothy Guilford

2013-03-29 Publication of PL1817006T3 publication Critical patent/PL1817006T3/pl

Links

RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title 2
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Dispersion Chemistry (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Inorganic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

PL05851408T 2004-11-07 2005-11-07 Liposomalny preparat do doustnego podawania glutationu (zredukowanego) PL1817006T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US52278504P	2004-11-07	2004-11-07
US59499605P	2005-05-25	2005-05-25
US59704105P	2005-11-06	2005-11-06
EP05851408A EP1817006B1 (en)	2004-11-07	2005-11-07	Liposomal formulation for oral administration of glutathione (reduced)
PCT/US2005/040308 WO2006060120A2 (en)	2004-11-07	2005-11-07	Liposomal formulation for oral administration of glutathione (reduced)

Publications (1)

Publication Number	Publication Date
PL1817006T3 true PL1817006T3 (pl)	2013-03-29

Family

ID=36565495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05851408T PL1817006T3 (pl)	2004-11-07	2005-11-07	Liposomalny preparat do doustnego podawania glutationu (zredukowanego)

Country Status (7)

Country	Link
EP (1)	EP1817006B1 (pl)
JP (2)	JP5112876B2 (pl)
CA (1)	CA2628777C (pl)
ES (1)	ES2395555T3 (pl)
IL (1)	IL182950A (pl)
PL (1)	PL1817006T3 (pl)
WO (1)	WO2006060120A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006105155A2 (en) *	2005-03-29	2006-10-05	Guilford Timothy F	Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms
WO2011036557A1 (en) *	2009-09-22	2011-03-31	The University Of British Columbia	Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
WO2011082283A2 (en) *	2009-12-30	2011-07-07	Guilford F Timothy	Management of myoclonus with oral liposomal reduced glutathione
US10016389B2 (en)	2011-01-05	2018-07-10	Livon Laboratories	Method of making liposomes, liposome compositions made by the methods, and methods of using the same
WO2013103840A1 (en) *	2012-01-05	2013-07-11	Guilford Frederick Timothy	Anti-cancer composition and method utilizing 3-bp and liposomal reduced glutathione
US20150030668A1 (en) *	2012-01-05	2015-01-29	Frederick Timothy Guilford	Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions
CA2925546C (en)	2012-10-29	2022-06-14	The University Of North Carolina At Chapel Hill	Methods and compositions for treating mucosal tissue disorders
EP2956153A4 (en) *	2013-02-15	2017-03-22	Your Energy Systems, LLC	Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione
TWI589308B (zh)	2014-03-25	2017-07-01	林信湧	一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法
CN110198728A (zh)	2016-11-17	2019-09-03	莱诺翁股份有限公司	用谷胱甘肽组合物治疗呼吸道疾病和感染
JP7339955B2 (ja)	2017-11-17	2023-09-06	レノビオンインコーポレイテッド	安定したアスコルビン酸組成物およびそれを使用する方法
KR102171719B1 (ko)	2018-11-14	2020-10-29	충남대학교산학협력단	경구투여용 글루타치온 함유 프로리포좀, 이를 포함하는 약제학적 조성물 및 이의 제조방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5746921A (en) *	1980-09-02	1982-03-17	Green Cross Corp:The	Oral preparation of human blood coagulation factor
FR2609393A1 (fr) *	1988-02-23	1988-07-15	Serobiologiques Lab Sa	Composition notamment utile comme matiere de base pour la preparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmetiques comprenant une substance azotee, notamment aminoacides, oligo- ou polypeptides, proteines, et leurs derives, et composition pharmaceutique ou cosmetique ainsi preparee.
US5238683A (en) *	1989-11-24	1993-08-24	The United States Of America As Represented By The Department Of Health And Human Services	Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
JP3272736B2 (ja) *	1991-01-31	2002-04-08	協和醗酵工業株式会社	リポソーム製剤
IT1257697B (it) *	1992-04-24	1996-02-01	Lifegroup Spa	N-acil derivati di aminoalcooli come agenti terapeutici attivi sull'edema neurogenico endoneurale a livello del nervo periferico.
US6764693B1 (en) *	1992-12-11	2004-07-20	Amaox, Ltd.	Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5607969A (en) *	1992-12-24	1997-03-04	Yissum Research Development Company Of The Hebrew University Of Jerusalem	L-DOPA ethyl ester to treat Parkinson's disease
JPH0859503A (ja) *	1994-08-26	1996-03-05	Teijin Ltd	ペプチド・蛋白質性薬物の経口、経粘膜投与用リポソーム製剤
US5500232A (en) *	1994-10-06	1996-03-19	Bristol-Myers Squibb Company	Calcium fortified beverages
US5891465A (en) *	1996-05-14	1999-04-06	Biozone Laboratories, Inc.	Delivery of biologically active material in a liposomal formulation for administration into the mouth
GB9620504D0 (en) *	1996-10-02	1996-11-20	Boehringer Ingelheim Ltd	Compositions
US6369106B1 (en) *	1996-12-26	2002-04-09	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
ATE448782T1 (de) *	1996-12-31	2009-12-15	Antioxidant Pharmaceuticals Co	Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
US6756056B2 (en) *	1997-04-08	2004-06-29	Alan A. Rubin	Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
US5829449A (en) *	1997-09-19	1998-11-03	Thione International, Inc.	Smoking products containing antioxidants
US6470894B2 (en) *	1997-09-19	2002-10-29	Thione International, Inc.	Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
US5994323A (en) *	1997-12-31	1999-11-30	P.N. Gerolymatos S.A.	Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6350470B1 (en) *	1998-04-29	2002-02-26	Cima Labs Inc.	Effervescent drug delivery system for oral administration
FR2777781B1 (fr) *	1998-04-24	2004-04-09	Rhone Poulenc Rorer Sa	Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US6011067A (en) *	1999-06-11	2000-01-04	Thione International, Inc.	Antioxidant composition for the treatment of psoriasis and related diseases
JP3989803B2 (ja) *	2002-09-18	2007-10-10	エーザイ・アール・アンド・ディー・マネジメント株式会社	食品腐敗菌の増殖抑制方法

2005
- 2005-11-07 CA CA2628777A patent/CA2628777C/en active Active
- 2005-11-07 JP JP2007539376A patent/JP5112876B2/ja active Active
- 2005-11-07 PL PL05851408T patent/PL1817006T3/pl unknown
- 2005-11-07 EP EP05851408A patent/EP1817006B1/en active Active
- 2005-11-07 ES ES05851408T patent/ES2395555T3/es active Active
- 2005-11-07 WO PCT/US2005/040308 patent/WO2006060120A2/en active Application Filing
2007
- 2007-05-03 IL IL182950A patent/IL182950A/en not_active IP Right Cessation
2012
- 2012-01-13 JP JP2012005488A patent/JP5571706B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2006060120A3 (en)	2006-09-14
JP2012102138A (ja)	2012-05-31
IL182950A (en)	2013-10-31
CA2628777A1 (en)	2006-06-08
CA2628777C (en)	2016-09-13
EP1817006B1 (en)	2012-09-05
JP5571706B2 (ja)	2014-08-13
WO2006060120A2 (en)	2006-06-08
ES2395555T3 (es)	2013-02-13
EP1817006A4 (en)	2009-12-02
EP1817006A2 (en)	2007-08-15
IL182950A0 (en)	2007-08-19
JP5112876B2 (ja)	2013-01-09
JP2008518976A (ja)	2008-06-05

Publication	Publication Date	Title
IL182950A0 (en)	2007-08-19	Liposomal formulation for oral administration of glutathione (reduced)
IL182967A0 (en)	2007-08-19	Liposomal formulation of bortezomib (ps-341)
IL177402A0 (en)	2006-12-10	Composition for oral administration of tamsulosin hydrochloride
EP1757273A4 (en)	2011-02-09	PREPARATION FOR ORAL ADMINISTRATION
AU2003229555A1 (en)	2003-09-16	Oral administration form for difficulty soluble basic active ingredients which are applied orally
EP1933862A4 (en)	2011-12-28	METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
IL176519A0 (en)	2006-10-05	Directly compressible pharmaceutical composition for the oral administration of cci-779
IL173808A0 (en)	2006-07-05	Pharmaceutical liposomal formulations
AU2003268087A1 (en)	2004-03-11	Liposomal gemcitabine compositions for better drug delivery
AU2003282782A8 (en)	2004-03-11	Pharmaceutically active lipid based formulation of sn38
EP1755633A4 (en)	2010-05-12	ORAL ADMINISTRATION OF PEPTIDE PHARMACEUTICAL COMPOSITIONS
HK1107271A1 (en)	2008-04-03	Method of enhancing absorptions of transmucosal administration formulations
AU2003246978A1 (en)	2004-02-23	Pharmaceutical compositions comprising cyclosporin for oral administration
IL180031A0 (en)	2007-05-15	Stable pharmaceutical formulations of benzimidazole compounds
HK1113308A1 (en)	2008-10-03	Pharmaceutical formulations of gallium salts
IL166337A0 (en)	2006-01-16	Oral administration of calctionin
EP1755568A4 (en)	2010-03-03	FORMULATION WITH CONTROLLED RELEASE FOR ORAL ADMINISTRATION OF METFORMIN
HK1102021A1 (en)	2007-11-02	Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative
AU2003284786A8 (en)	2004-06-23	Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
AU2003280387A1 (en)	2004-05-04	Pharmaceutical formulation comprising azithrocycin monohydrate
EP1626697A4 (en)	2010-06-09	PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION WITH LITHIUM CARBONATE
ZA200706110B (en)	2008-10-29	Pharmaceutical formulations of gallium salts
PL373776A1 (pl)	2005-10-03	Doustna kompozycja farmaceutyczna
GB0413138D0 (en)	2004-07-14	Preparation for oral administration
GB0225702D0 (en)	2002-12-11	Oral formulation of moisutre-sensitive drugs